Company Update

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) __________________ Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S. Employer incorporation)   Identification No.) 1221 Broadway , Oakland , California 94612-1888 (Address of principal executive offices) (Zip code) ( 510 ) 271-7000 (Registrant's telephone number, including area code) Not applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 Under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock - $1.00 par value CLX New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2). Emerging growth company      ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐       Item 8.01 Other Events. The Clorox Company (the “Company” or “Clorox”) has identified unauthorized activity on some of its Information Technology (IT) systems. After becoming aware of the activity, the Company began taking steps to stop and remediate the activity, including taking certain systems offline. The Company is working diligently to respond to and address this issue, and is also coordinating with law enforcement. To the extent possible, and in line with its business continuity plans, Clorox has implemented workarounds for certain offline operations in order to continue servicing its customers. However, the incident has caused, and is expected to continue to cause, disruption to parts of the Company’s business operations. Clorox has engaged leading third-party cybersecurity experts to support its investigation and recovery efforts. The investigation to assess the nature and scope of the incident remains ongoing and is in its early stages. Forward-Looking Statements This Current Report on Form 8-K contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. All statements other than statements of historical fact made herein are forward-looking statements, including without limitation statements about the extent and impact of the unusual system activity and related activities. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including, without limitation, those risk factors set forth in Item 1A of the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission for the fiscal year ended June 30, 2023. Actual results may differ materially from those in the forward-looking statements as a result of various factors, many of which are beyond the Company's control. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Item 9.01 Financial Statements and Exhibits (d) Exhibits See the Exhibit Index below. EXHIBIT INDEX                   Exhibit   Description 104   Cover Page Interactive Data File (embedded within the Inline XBRL document)     SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.     THE CLOROX COMPANY   Date:  August 14, 2023 By:  /s/ Angela Hilt       Angela Hilt       Executive Vice President – Chief Legal Officer